March 28, 2019 News by Larry Luxner MS Patient Groups React Favorably to Mayzent Approval, But Question Therapyās Price Tag National organizations that represent patients with multiple sclerosisĀ (MS) welcome the U.S. Food and Drug Administration’s March 26 approvalĀ of Novartis’Ā oral therapy MayzentĀ (siponimod) ā but they complain that, at $88,500 per year, the treatment is overpriced. The Multiple Sclerosis Society of AmericaĀ (MSSA) is clearly upbeat about the…
March 20, 2019 News by Jose Marques Lopes, PhD SPMS Treatment With Mayzent Better Than Best Supportive Care, ICER Report Says Treatment of secondary progressive multiple sclerosis (SPMS) patients with the investigational oral therapy Mayzent (siponimod) significantly reduced the risk of disability progression and decreased inflammation, compared to best supportive care, according to aĀ preliminary draft evidence reportĀ from the Institute for Clinical and Economic Review (ICER). The report…
February 17, 2017 Columns by Ed Tobias MS Drug Costs: The Elephant in the Examination Room A lot of factors go into our decisions when we selectĀ the drug we’re going to use to fight our multiple sclerosis. How well will it work? What are the possible side effects and how serious could they be? How will using the drug (taking a pill, giving myself a…
December 1, 2016 News by Patricia Silva, PhD ICER Releases Draft Report on Disease-modifying Therapies for MS, Welcomes Comment The Institute for Clinical and Economic Review (ICER) has released aĀ Draft Evidence ReportĀ evaluating the comparative clinical effectiveness and value of disease-modifying therapies (DMTs) for patients with relapsing-remitting and primary-progressive forms of multiple sclerosis (MS). Through Dec. 21, patients, the public, and other stakeholders can accessĀ the 82-page report and…
November 8, 2016 News by Patricia Silva, PhD Plans by 4 Countries to Subsidize Cost of Newer MS Drugs May Weight on US A cost-effectiveness analysis of reimbursement recommendationsĀ for four relatively new multiple sclerosis (MS) treatments made by agencies in four countries ā Australia, Canada, Sweden, and the U.K. ā found overwhelming support (88 percent) for either full or restricted reimbursement for each therapy. The analysis, performed by theĀ Decision Resources Group, is…
July 18, 2016 News by Charles Moore Closer Look at ICER, Group Now Weighing Efficacy and Benefits of RRMS Therapies The Institute of Clinical and Economic Review (ICER), the nonprofit organization thatĀ released a preliminary draft last week intended to shapeĀ the Institute’s forthcoming report onĀ the effectiveness and benefits of therapies for relapsing-remitting multiple sclerosis (RRMS), is made up of experts in healthcare policy from across the U.S. who, through the…
July 8, 2016 Columns by admin Have Your Say About Disease Modifying Therapies for RRMS You have just one week from today to have your say about the effectiveness of various disease modifying therapies (DMT) used to treat relapsing remitting multiple sclerosis (RRMS). Public comments are welcome in response to an early draft paper that is planned to be the basis for…